(Q24235797)

4

0 references

Manit Srisurapanont

5

object named as

Manit Srisurapanont

0 references

Michael Soyka

6

object named as

Michael Soyka

0 references

author name string

Susanne Rösner

1

0 references

Andrea Hackl-Herrwerth

Cochrane Database of Systematic Reviews

2

0 references

publication date

8 December 2010

0 references

published in

0 references

cites work

A multi-site dose ranging study of nalmefene in the treatment of alcohol dependence

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001867.PUB3

Naltrexone combined with either cognitive behavioral or motivational enhancement therapy for alcohol dependence

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001867.PUB3

Combined pharmacotherapies and behavioral interventions for alcohol dependence: the COMBINE study: a randomized controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001867.PUB3

A 6-month controlled naltrexone study: combined effect with cognitive behavioral therapy in outpatient treatment of alcohol dependence

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001867.PUB3

Comparing topiramate with naltrexone in the treatment of alcohol dependence

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001867.PUB3

A randomized, double-blind, placebo-controlled pilot study of naltrexone in outpatients with bipolar disorder and alcohol dependence

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001867.PUB3

Efficacy and tolerability of long-acting injectable naltrexone for alcohol dependence: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001867.PUB3

Lack of efficacy of naltrexone in the prevention of alcohol relapse: results from a German multicenter study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001867.PUB3

A double-blind, placebo-controlled study of naltrexone in the treatment of alcohol-dependence disorder: results from a multicenter clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001867.PUB3

Targeted use of naltrexone without prior detoxification in the treatment of alcohol dependence: a factorial double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001867.PUB3

A double-blind, placebo-controlled study of naltrexone in the treatment of alcohol dependence in Taiwan

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001867.PUB3

A pilot evaluation of the safety and tolerability of repeat dose administration of long-acting injectable naltrexone (Vivitrex) in patients with alcohol dependence

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001867.PUB3

Comparing and combining naltrexone and acamprosate in relapse prevention of alcoholism: a double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001867.PUB3

Effectiveness of naltrexone in a community treatment program

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001867.PUB3

Naltrexone vs. nefazodone for treatment of alcohol dependence. A placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001867.PUB3

Naltrexone depot for treatment of alcohol dependence: a multicenter, randomized, placebo-controlled clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001867.PUB3

Aripiprazole in the treatment of patients with alcohol dependence: a double-blind, comparison trial vs. naltrexone

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001867.PUB3

A double-blind, placebo-controlled pilot study to evaluate the efficacy and safety of oral nalmefene HCl for alcohol dependence

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001867.PUB3

A double-blind, placebo-controlled study of oral nalmefene for alcohol dependence

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001867.PUB3

Predicting treatment response to naltrexone: the influence of craving and family history

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001867.PUB3

Naltrexone versus acamprosate in the treatment of alcohol dependence: A multi-centre, randomized, double-blind, placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001867.PUB3

Naltrexone for alcohol dependence: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001867.PUB3

Naltrexone alone and with sertraline for the treatment of alcohol dependence in Alaska natives and non-natives residing in rural settings: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001867.PUB3

A placebo-controlled randomized clinical trial of naltrexone in the context of different levels of psychosocial intervention

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001867.PUB3

Naltrexone augmentation of neuroleptic treatment in alcohol abusing patients with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001867.PUB3

Naltrexone and disulfiram in patients with alcohol dependence and comorbid psychiatric disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001867.PUB3

A double blind, placebo-controlled trial that combines disulfiram and naltrexone for treating co-occurring cocaine and alcohol dependence

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001867.PUB3

Gender differences with high-dose naltrexone in patients with co-occurring cocaine and alcohol dependence

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001867.PUB3

Treatment of cocaine-alcohol dependence with naltrexone and relapse prevention therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001867.PUB3

High-dose naltrexone therapy for cocaine-alcohol dependence

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001867.PUB3

Naltrexone in the treatment of alcohol dependence

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001867.PUB3

Prescription procedures in medication for relapse prevention after inpatient treatment for alcohol use disorders in Switzerland.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001867.PUB3

Gamma-hydroxybutyric acid versus naltrexone in maintaining alcohol abstinence: an open randomized comparative study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001867.PUB3

Comparing and combining gamma-hydroxybutyric acid (GHB) and naltrexone in maintaining abstinence from alcohol: an open randomised comparative study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001867.PUB3

The safety profile of naltrexone in the treatment of alcoholism. Results from a multicenter usage study. The Naltrexone Usage Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001867.PUB3

Naltrexone and brief counseling to reduce heavy drinking in hazardous drinkers

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001867.PUB3

Naltrexone's suppressant effects on drinking are limited to the first 3 months of treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001867.PUB3

A one-year pragmatic trial of naltrexone vs disulfiram in the treatment of alcohol dependence

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001867.PUB3

Naltrexone treatment of adolescent alcoholics: an open-label pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001867.PUB3

Effects of naltrexone and nalmefene on subjective response to alcohol among non-treatment-seeking alcoholics and social drinkers

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001867.PUB3

Single- and multiple-dose pharmacokinetics of long-acting injectable naltrexone

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001867.PUB3

A double-blind, placebo-controlled study of sertraline with naltrexone for alcohol dependence

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001867.PUB3

Pharmacokinetics, safety, and tolerability of a depot formulation of naltrexone in alcoholics: an open-label trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001867.PUB3

Patterns of dispensed disulfiram and naltrexone for alcoholism treatment in a veteran patient population

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001867.PUB3

Dose-ranging kinetics and behavioral pharmacology of naltrexone and acamprosate, both alone and combined, in alcohol-dependent subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001867.PUB3

Targeted nalmefene with simple medical management in the treatment of heavy drinkers: a randomized double-blind placebo-controlled multicenter study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001867.PUB3

Using naltrexone in inpatient alcoholism treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001867.PUB3

Targeted naltrexone treatment moderates the relations between mood and drinking behavior among problem drinkers

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001867.PUB3

Persistence with oral naltrexone for alcohol treatment: implications for health-care utilization.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001867.PUB3

A randomized, multicentre, open-label, comparative trial of disulfiram, naltrexone and acamprosate in the treatment of alcohol dependence

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001867.PUB3

High and low dosage oxcarbazepine versus naltrexone for the prevention of relapse in alcohol-dependent patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001867.PUB3

A pharmacokinetic and pharmacodynamic drug interaction study of acamprosate and naltrexone

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001867.PUB3

Effects of naltrexone on cue-elicited craving for alcohol and cocaine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001867.PUB3

Effect of naltrexone and ondansetron on alcohol cue-induced activation of the ventral striatum in alcohol-dependent people

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001867.PUB3

Comparing treatments of alcoholism on craving and biochemical measures of alcohol consumptionst.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001867.PUB3

Initial and maintenance naltrexone treatment for alcohol dependence using primary care vs specialty care: a nested sequence of 3 randomized trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001867.PUB3

The effect of naltrexone and acamprosate on cue-induced craving, autonomic nervous system and neuroendocrine reactions to alcohol-related cues in alcoholics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001867.PUB3

The effects of naltrexone on alcohol and cocaine use in dually addicted patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001867.PUB3

Effects of naltrexone on alcohol sensitivity and genetic moderators of medication response: a double-blind placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001867.PUB3

Naltrexone versus acamprosate: one year follow-up of alcohol dependence treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001867.PUB3

Naltrexone improves outcome of a controlled drinking program.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001867.PUB3

Clinical predictors of response to naltrexone in alcoholic patients: who benefits most from treatment with naltrexone?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001867.PUB3

An open randomized study of the treatment of escitalopram alone and combined with gamma-hydroxybutyric acid and naltrexone in alcoholic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001867.PUB3

Moderators of naltrexone's effects on drinking, urge, and alcohol effects in non-treatment-seeking heavy drinkers in the natural environment

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001867.PUB3

A randomized control trial of group counseling in a naltrexone treatment program

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001867.PUB3

Chlorpromazine versus placebo for schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001867.PUB3

Reward-motivated learning: mesolimbic activation precedes memory formation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001867.PUB3

Alteration of ethanol self-administration by naltrexone.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001867.PUB3

Posttreatment results of combining naltrexone with cognitive-behavior therapy for the treatment of alcoholism

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001867.PUB3

An evaluation of mu-opioid receptor (OPRM1) as a predictor of naltrexone response in the treatment of alcohol dependence: results from the Combined Pharmacotherapies and Behavioral Interventions for Alcohol Dependence (COMBINE) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001867.PUB3

Antidepressants versus placebo for depression in primary care

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001867.PUB3

Efficacy and safety of naltrexone and acamprosate in the treatment of alcohol dependence: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001867.PUB3

A comparison of statistical methods for meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001867.PUB3

Treatment of cocaine and alcohol dependence with psychotherapy and disulfiram

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001867.PUB3

Empirical evidence for selective reporting of outcomes in randomized trials: comparison of protocols to published articles

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001867.PUB3

Compelling or irrelevant? Using number needed to treat can help decide

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001867.PUB3

Pharmacologic profile of NPC 168 (naltrexone phenyl oxime), a novel compound with activity at opioid receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001867.PUB3

Meta-analysis in clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001867.PUB3

Nalmefene: safety and kinetics after single and multiple oral doses of a new opioid antagonist

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001867.PUB3

Bias in meta-analysis detected by a simple, graphical test

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001867.PUB3

Prolonged blockade of opioid effect with oral nalmefene

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001867.PUB3

Endogenous opioids and addiction to alcohol and other drugs of abuse

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001867.PUB3

Effects of Naltrexone Alone and In Combination With Acamprosate on the Alcohol Deprivation Effect in Rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001867.PUB3

Measuring inconsistency in meta-analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001867.PUB3

Effects of opiate antagonist treatment on the alcohol deprivation effect in long-term ethanol-experienced rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001867.PUB3

Quality of Reporting of Randomized Trials as a Measure of Methodologic Quality

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001867.PUB3

Prolonged central mu-opioid receptor occupancy after single and repeated nalmefene dosing

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001867.PUB3

Long-term effects of pharmacotherapy on relapse prevention in alcohol dependence.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001867.PUB3

Efficacy of Naltrexone and Acamprosate for Alcoholism Treatment: A Meta-Analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001867.PUB3

Different roles of mu-, delta- and kappa-opioid receptors in ethanol-associated place preference in rats exposed to conditioned fear stress

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001867.PUB3

Naltrexone effects on ethanol consumption and response to ethanol conditioned cues in C57BL/6 mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001867.PUB3

Use of the CONSORT statement and quality of reports of randomized trials: a comparative before-and-after evaluation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001867.PUB3

Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001867.PUB3

Active placebos versus antidepressants for depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001867.PUB3

Rates and predictors of relapse after natural and treated remission from alcohol use disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001867.PUB3

Intention-to-treat analysis: implications for quantitative and qualitative research

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001867.PUB3

Confirmation bias: A ubiquitous phenomenon in many guises

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001867.PUB3

A functional polymorphism of the mu-opioid receptor gene is associated with naltrexone response in alcohol-dependent patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001867.PUB3

Simple pattern-mixture models for longitudinal data with missing observations: analysis of urinary incontinence data

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001867.PUB3

Impact of allocation concealment on conclusions drawn from meta-analyses of randomized trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001867.PUB3

Statistical problems in the reporting of clinical trials. A survey of three medical journals.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001867.PUB3

Matching Alcoholism Treatments to Client Heterogeneity: Project MATCH posttreatment drinking outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001867.PUB3

Global burden of disease and injury and economic cost attributable to alcohol use and alcohol-use disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001867.PUB3

A systematic review of the effectiveness of naltrexone in the maintenance treatment of opioid and alcohol dependence

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001867.PUB3

Acamprosate supports abstinence, naltrexone prevents excessive drinking: evidence from a meta-analysis with unreported outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001867.PUB3

Undue reliance on I(2) in assessing heterogeneity may mislead

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001867.PUB3

Evidence about the use of naltrexone and for different ways of using it in the treatment of alcoholism

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001867.PUB3

Alcohol abusers' perceptions of the accuracy of their self-reports of drinking: implications for treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001867.PUB3

Quetiapine for schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001867.PUB3

Opioid antagonists for alcohol dependence

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001867.PUB3

Naltrexone for the treatment of alcoholism: a meta-analysis of randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001867.PUB3

The Development of a Questionnaire to Measure Severity of Alcohol Dependence *

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001867.PUB3

Naltrexone, a relapse prevention maintenance treatment of alcohol dependence: a meta-analysis of randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001867.PUB3

Assessment of alcohol withdrawal: the revised clinical institute withdrawal assessment for alcohol scale (CIWA-Ar).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001867.PUB3

False-positive results in clinical trials: multiple significance tests and the problem of unreported comparisons.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001867.PUB3

Effect of naltrexone on alcohol "high" in alcoholics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001867.PUB3

Outcome selection bias in meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001867.PUB3

Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta-epidemiological study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001867.PUB3

Psychotherapy for opiate addicts. Does it help?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001867.PUB3

Pharmacologic Interventions for Alcohol- and Cocaine-Abusing Individuals: A Pilot Study of Disulfiram vs. Naltrexone

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001867.PUB3

Analysing Data and Undertaking Meta-Analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001867.PUB3

Naltrexone and coping skills therapy for alcohol dependence. A controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001867.PUB3

7 January 2021

Naltrexone and alcohol dependence. Role of subject compliance

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001867.PUB3

7 January 2021

Subverting randomization in controlled trials.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001867.PUB3

7 January 2021

Cochrane Database of Systematic Reviews

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001867.PUB3

7 January 2021

The Hopkins Symptom Checklist (HSCL): A self-report symptom inventory

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001867.PUB3

7 January 2021

Naltrexone treatment of comorbid alcohol and cocaine use disorders

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001867.PUB3

7 January 2021

Targeted naltrexone treatment of early problem drinkers

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001867.PUB3

7 January 2021

Alcohol dependence syndrome: measurement and validation

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001867.PUB3

7 January 2021

Influence of naltrexone on cue-elicited craving among hazardous drinkers: the moderational role of positive outcome expectancies.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001867.PUB3

7 January 2021

Naltrexone in the treatment of alcohol dependence

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001867.PUB3

7 January 2021

Naltrexone exerts a favourable effect on plasma lipids in abstinent patients with alcohol dependence

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001867.PUB3

7 January 2021

A multicentre, randomized, double-blind, placebo-controlled trial of naltrexone in the treatment of alcohol dependence or abuse

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001867.PUB3

7 January 2021

An improved diagnostic evaluation instrument for substance abuse patients. The Addiction Severity Index.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001867.PUB3

7 January 2021

Naltrexone as an adjunctive treatment for older patients with alcohol dependence

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001867.PUB3

7 January 2021

Development of a questionnaire to measure alcohol dependence

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001867.PUB3

7 January 2021

Targeted versus daily naltrexone: secondary analysis of effects on average daily drinking

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001867.PUB3

7 January 2021

Building better cognitive-behavioral therapy: is broad-spectrum treatment more effective than motivational-enhancement therapy for alcohol-dependent patients treated with naltrexone?

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001867.PUB3

7 January 2021

Direct and indirect costs attributable to alcohol consumption in Germany

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001867.PUB3

7 January 2021

10.1002/14651858.CD001867.PUB3

Identifiers

DOI

1 reference

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

4425596

OpenCitations bibliographic resource ID

4425596

1 reference